MedImmune adds VPs
MedImmune promotes three employees to newly created VP posts: Cynthia Oliver to VP of process biochemistry and formulation sciences; Kripa Ram to VP of bioprocess and manufacturing sciences; and Mark Schenerman to VP of analytical biochemistry. The company also hires Jessie Groothuis as VP and head of medical & scientific affairs, infectious disease. She will be responsible for the late-stage clinical programs for MedImmune's marketed infectious disease products, such as Synagis (palivizumab) and FluMist...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.